Prostate Cancer Screening (PDQ®): Screening - Health Professional Information [NCI] - Significance
Incidence and Mortality Prostate cancer is the most common cancer diagnosed in North American men,excluding skin cancers. It is estimated that in 2006,approximately 234,460 new cases and 27,350 prostate cancer-related deaths will occur in the United States.[ 1 ] Prostate cancer is now the third leading cause of cancer death in men,exceeded only by lung cancer and colorectal cancer. It ...
Prostate Cancer Treatment (PDQ®): Treatment - Health Professional Information [NCI] - Stage I Prostate Cancer Treatment
OverviewStage I prostate cancer is defined by the American Joint Committee on Cancer's TNM classification system:T1a–c, N0, M0, prostate-specific antigen (PSA) <10 ng/ml, Gleason ≤6.T2a, N0, M0, PSA <10 ng/ml, Gleason ≤6.T1–2a, N0, M0, PSA X, Gleason X.The frequency of clinically silent, nonmetastatic prostate cancer that can be found at autopsy greatly increases with age and may be as high as 50% to 60% in men aged 90 years and older. Undoubtedly, the incidental discovery of these occult cancers at prostatic surgery performed for other reasons accounts for the similar survival of men with stage I prostate cancer, compared with the normal male population, adjusted for age. Many stage I cancers are well differentiated and only focally involve the gland (T1a, N0, M0); most require no treatment other than careful follow-up.In younger patients (aged 50–60 years) whose expected survival is long, treatment should be considered. Radical
Prostate Cancer Prevention (PDQ®): Prevention - Health Professional Information [NCI] - Changes to This Summary (02 / 15 / 2013)
The PDQ cancer information summaries are reviewed regularly and updated as new information becomes available. This section describes the latest changes made to this summary as of the date above.SignificanceUpdated statistics with estimated new cases and deaths for 2013 (cited American Cancer Society as reference 1).This summary is written and maintained by the PDQ Screening and Prevention Editorial Board, which is editorially independent of NCI. The summary reflects an independent review of the literature and does not represent a policy statement of NCI or NIH. More information about summary policies and the role of the PDQ Editorial Boards in maintaining the PDQ summaries can be found on the About This PDQ Summary and PDQ NCI's Comprehensive Cancer Database pages.
Prostate Cancer Treatment (PDQ®): Treatment - Patient Information [NCI] - Treatment Options by Stage
Stage I Prostate Cancer Treatment of stage I prostate cancer may include the following: Watchful waiting. Radical prostatectomy,usually with pelvic lymphadenectomy,with or without radiation therapy after surgery. It may be possible to remove the prostate without damaging nerves that are necessary for an erection. External-beam radiation therapy. Implant radiation therapy. A clinical trial ...
Prostate Cancer Prevention (PDQ®): Prevention - Health Professional Information [NCI] - Risk Factors for Prostate Cancer Development
Age Prostate cancer incidence increases dramatically with increasing age. While a very unusual disease in men younger than 50 years,rates increase exponentially thereafter. The registration rate by age cohort in England and Wales increased from 8 per thousand population in men aged 50 to 56 years to 68 per thousand in men aged 60 to 64 years,260 per thousand in men aged 70 to 74 years,and ...
Prostate Cancer Screening (PDQ®): Screening - Health Professional Information [NCI] - Evidence of Benefit
Prior to the 1990s,the digital rectal examination (DRE) was the test traditionally mentioned for prostate cancer screening. Two other test procedures are also available: transrectal ultrasound (TRUS) imaging and serum prostate-specific antigen (PSA) concentrations.[ 1 ] Prostate cancer screening is controversial because of the lack of definitive evidence of benefit. A small randomized trial in .
Prostate Cancer Screening (PDQ®): Screening - Patient Information [NCI] - Questions or Comments About This Summary
If you have questions or comments about this summary,please send them to Cancer.gov through the Web site’s Contact Form. We can respond only to email messages written in English. ...
Prostate Cancer Prevention (PDQ®): Prevention - Patient Information [NCI] - Get More Information From NCI
Sources of further information about Prostate Cancer Prevention.
Prostate Cancer Treatment (PDQ®): Treatment - Health Professional Information [NCI] - Recurrent Prostate Cancer Treatment
OverviewIn recurrent prostate cancer, the selection of further treatment depends on many factors, including:Previous treatment.Site of recurrence.Coexistent illnesses.Individual patient considerations. Definitive radiation therapy can be given to patients with disease that fails only locally following prostatectomy.[1,2,3,4] An occasional patient can be salvaged with prostatectomy after a local recurrence following definitive radiation therapy; however, only about 10% of patients treated initially with radiation therapy will have local relapse only. In these patients, prolonged disease control is often possible with hormonal therapy, with median cancer-specific survival of 6 years after local failure.Cryosurgical ablation of recurrence following radiation therapy is associated frequently with a high complication rate. This technique is still undergoing clinical evaluation.Hormonal therapy is used to manage most relapsing patients with disseminated
Prostate Cancer Treatment (PDQ®): Treatment - Patient Information [NCI] - To Learn More About Prostate Cancer
For more information from the National Cancer Institute about prostate cancer,see the following: Prostate Cancer What You Need to Know About™ Prostate Cancer Prostate Cancer Prevention Prostate Cancer Screening Treatment Choices for Men with Early-Stage Prostate Cancer Early Prostate Cancer: Questions and Answers The Prostate-Specific Antigen (PSA) Test: Questions and Answers Cryosurgery in ...